Clarithromycin Stella Drug Interactions

Theophylline: Clarithromycin use in patients who are receiving theophylline may be associated with an increase of serum theophylline concentrations.
Carbamazepine: Concomitant administration of single doses of clarithromycin and carbamazepine has been shown to result in increased plasma concentrations of carbamazepine. Blood level monitoring of carbamazepine may be considered.
Anticoagulants: Concomitant administration of clarithromycin and oral anticoagulants may potentiate the effects of the oral anticoagulant.
Digoxin: Elevated serum concentrations of digoxin.
Terfenadine: When clarithromycin and terfenadine were coadministered, plasma concentrations of the active acid metabolite of terfenadine were threefold higher, on average, than the values observed when terfenadine was administered alone.
Ritonavir: When clarithromycin is used in patients receiving ritonavir, modification of the usual clarithromycin dosage generally is not necessary in those with normal renal function; however, the clarithromycin dosage should be reduced by 50% in patients with creatinine clearances of 30-60 ml/minute and reduced by 75% in patients with creatinine clearances less than 30 ml/minute.
Co-administration of Clarithromycin, known to inhibit CYP34, and a drug primarily metabolized by CYP34 may be associated with elevations in drug concentrations that could increase or prolong both therapeutic and adverse effects of the concomitant drug.
The following drugs or drug classes are known or suspected to be metabolized by CYP34 isozyme: Domperidone.